Clinical trial · Interventional
Ketogenic Diet for Recurrent Glioblastoma
Ketogenic Diet for Patients With Recurrent Glioblastoma
NCT00575146CI-TRIAL-00014405ERGOcompletedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine whether a mild ketogenic diet can influences quality of life and survival of patients with recurrent glioblastoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TAVARLIN | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- ketogenic diet
- interventionNames
- Dietary Supplement: TAVARLIN
Primary outcomes (1)
- measure
- Applicability as Measured by Discontinuation of Study Treatment Due to Intolerability
- timeFrame
- until progression for up to 12 months
- description
- percentage of patients who discontinued diet due to intolerability
Secondary outcomes (5)
- measure
- Progression-free-survival
- timeFrame
- until progression for up to 12 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * age \>= 18 years * histological diagnosis of glioblastoma or gliosarcoma * on MRI measurable tumor * interval of at least 6 months after primary resection * completed radiotherapy, interval of at least 3 months after completion of radiotherapy * relapse during or after temozolomide chemotherapy, other chemotherapy not possible, not reasonable or not wanted by the patient * Karnofsky-Index \>= 60%, ECOG \<= 2 * life expectancy of at least 12 weeks * creatinine \<= 1.5 mg/dl, urea \<= 50 mg/dl * INR \<= 1,5, GOT \<= 7 x of normal value, GPT \<= 7 x of normal value Exclusion Criteria: * bowel obstruction or subileus * diabetes mellitus, HbA1c \> 6,1 % * heart failure (NYHA \> 2), myocardial infarction within the last 6 months, atrial fibrillation * acute infection * conditions that may strongly reduce compliance to the diet or increase risk of the diet * dementia or clinically relevant alterations of the mental state which interfere with the applicability of the diet
References
Publications (1)
- RESULTRieger J, Bahr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kammerer U, Coy JF, Weller M, Steinbach JP. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014 Jun;44(6):1843-52. doi: 10.3892/ijo.2014.2382. Epub 2014 Apr 11. PMID 24728273